Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Hoffmann J, Spengler M: Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study
REWIND expanded the evidence base by studying dulaglutide (1.5 mg/week subcutaneous) in a broader population that included a substantial proportion of primary prevention patientsonly 31% of its 9,903 participants had established cardiovascular disease at baseline [3]
A systematic review and meta-analysis by Yao et al demonstrated that GLP-1 RAs were superior to placebo in reducing hemoglobin A1c (HbA1c) and fasting plasma glucose levels in patients with T2DM
However, eligibility is not just about the medication itself
If your clinician determines that a compounded medication is clinically appropriate for you, please be aware that it is not an FDA-approved product
